Jazz Pharmaceuticals Plc Q3 FY2026 earnings call

• Strategic Growth & Launches: Achieved record revenues of $1.24 billion (+10% YoY). Key milestone was the FDA approval and launch of Zyhera for first-line HER2-positive metastatic gastric adenocarcinoma (GEA), with peak sales potential estimated at $3–5 billion.
• Commercial Execution: Strong performance across the portfolio. Zywave maintained momentum despite generic competition, aided by its low-sodium profile and cardiovascular safety data from the DUET trial. Epidiolex sales reached $295M, supported by strong patient persistence via Jazz Cares nurse navigator programs.
• Pipeline Advancements: Completed acquisition of Actio Biosciences, adding ABS 1230 (a KCNT1 inhibitor for rare epilepsy) to the pipeline. Presented final Horizon GEA-01 trial data at ESMO showing a 24% reduction in risk of death vs. trastuzumab. Initiated Phase 1 trials for JZP269 (orexin 2 receptor agonist).
• Leadership Transition: Chief Commercial Officer Sam Pearce announced her retirement after leading key launches including Epidiolex’s blockbuster status and recent oncology introductions; she will remain through the transition period.
• Financial Discipline: Generated $1.3 billion in operating cash flow in the first nine months. Issued $1.25 billion in convertible notes while extending term loan maturity. Maintained disciplined capital allocation despite significant R&D and commercial investments.

• Rare Sleep: Net product sales of $778 million (Zywave $483M, Zyrtec/Zylo implied remainder or other sleep products). Zywave grew 12% YoY to $483M. This segment contributed approximately 63% of total revenue.
• Oncology: Net product sales of $329 million. Driven by Medezo (~$200M), Zepzelka ($104M, +32% YoY), and Zyhera ($21M in its first full quarter). Oncology revenues grew 35% YoY, contributing approximately 27% of total revenue.
• Other/Total: Total net product sales were $1.24 billion, a 10% increase year-over-year.

• Revenue Guidance: Raised and narrowed total 2026 revenue guidance to $4.775–$4.85 billion (midpoint ~13% growth over 2025). The new low end exceeds the prior high end.
• Rare Sleep Guidance: Increased rare sleep revenue guidance to $2.125–$2.175 billion, driven by low-double-digit to low-teens Zywave growth and slower-than-expected uptake of high-sodium generics.
• Margin Guidance: Increased non-GAAP gross margin guidance by 50 basis points to 90.5%–91.5%, reflecting higher sales volume and mix.
• Expense Guidance: Non-GAAP SG&A and R&D expense guidance remains unchanged, reflecting disciplined cost management.
• Tax Rate: Updated non-GAAP effective tax rate to 19.5%–21.5% to account for the non-tax-deductible acquired IPR&D charge from the Actio acquisition.
• Share Count: Guidance for weighted average shares remains unchanged at 69–70 million.

• Competitive Pressure: Future headwinds anticipated for Zepzelka in 2027 due to competitor launches in first-line maintenance extensive stage small cell lung cancer (e.g., Amgen's MDELTRA). Orexin-2 receptor agonists may extend initiation time for new Zywave patients, though stable patients are expected to remain on therapy.
• Regulatory/Litigation: Past antitrust litigation settlements for Avidel and Xyrem incurred significant charges ($151.5M in Q3 2025); ongoing regulatory scrutiny in rare disease and oncology spaces.
• Operational Execution Risks: Dependency on successful community-level adoption for Zyhera in GEA, as opposed to academic centers. Potential delays in clinical trial timelines or data readouts (e.g., ACTION trial, EMPOWER BC303).
• Market Access: Reimbursement challenges or administrative lags could impact uptake, although current formulary access for Zyhera has been described as frictionless.
• Integration Risks: Post-acquisition integration risks associated with Actio Biosciences and the ABS 1230 program.

Q: Analyst asked about factors driving the raised guidance, specifically if it was solely due to rare sleep or other areas. / A: CFO Phil Johnson stated that over half the increase came from rare sleep (Zywave) due to outstanding execution and slower-than-expected generic erosion. The rest was driven by strong performance in Europe and US oncology/Epidiolex, which mitigated potential downside scenarios without increasing operating expense guidance.

Q: Analyst asked about physician experience in community settings using HER2-targeted agents for Zyhera and diagnosis strategy lag compared to academics. / A: CCO Sam Pearce highlighted that 80% of new ordering accounts in September came from community settings, showing rapid penetration. Brand awareness is high (43% unaided), and 79% of surveyed oncologists report high intent to prescribe. The strategy focuses on mobilizing community infrastructure where the majority of GEA patients are treated.

Q: Analyst asked about the proportion of single-patient orders vs. repeat clinic orders for Zyhera and feedback on adherence/dose modifications. / A: Sam Pearce clarified that the threefold increase in accounts represented first-time ordering accounts, predominantly from community clinics. While too early for persistence data, reimbursement and pathway adoption have been frictionless. Investments in nurse educators and starter kits are supporting seamless onboarding without significant dose modification issues.

Q: Analyst asked about Zyhera’s addressable patient distribution in GEA compared to BTC and ramp dynamics. / A: Sam Pearce noted GEA demand is predominantly community-heavy, unlike BTC. Crucially, there was no bolus of expanded access or trial patients transitioning to commercial use; all demand reflects new patient starts. As community clinics integrate the regimen, momentum is expected to build into Q4 and beyond.

Q: Analyst asked about NCCN guideline upgrade opportunity for Zyhera given updated OS data and whether community uptake is hindered by current Category 2a status. / A: Renee Gala and Sam Pearce confirmed mature OS data (27-month median OS) has been submitted to NCCN for Category 1 consideration. However, current Category 2a preferred status already ensures broad reimbursement and pathway access. Community adoption remains strong (80% of new accounts), proving the current designation does not impede clinical uptake.